From DNA To Nanoparticles: Exploring Modern Vaccine Technologies |...

From DNA To Nanoparticles: Exploring Modern Vaccine Technologies

نشر بتاريخ 2024-03-22 09:59:33

1كيلو بايت

Scientific breakthroughs over the past few decades have revolutionized vaccine development. Using recombinant DNA techniques, researchers can now design vaccines targeting specific pathogens more precisely and efficiently. Previously, vaccines were developed using weakened or inactivated whole viruses and bacteria. While effective, this traditional approach had limitations. Scientists now have tools to dissect the genetic material of pathogens and produce only the key components needed to elicit an immune response.

DNA Vaccines

One innovative technology is DNA Vaccine Technologies. Instead of delivering inactivated or live attenuated pathogens, DNA vaccines introduce genetic material—DNA plasmids—into host cells. The plasmids contain genetic instructions for making antigens found on pathogen surfaces. Host cells then produce these foreign antigens, training the immune system to recognize and attack the real pathogen. DNA vaccine twchnologies offer numerous advantages—they can be rapidly produced without the need to grow live pathogens, several antigens can be targeted at once, and they produce longer-lasting immune memory compared to traditional vaccines. However, more research is still needed to optimize DNA delivery methods and increase immune responses.

Recombinant Subunit Vaccines

By isolating specific pathogen proteins or enzymes, researchers have developed recombinant subunit vaccines. The first approved recombinant vaccine was Hebernex, targeting hepatitis B virus surface antigens produced in yeast cells. Now many others have followed, such as vaccines for hepatitis B, papillomavirus, and pertussis that focus the immune response precisely on key viral or bacterial antigens. Without whole pathogens, subunit vaccines eliminate the risk of infection and are often better tolerated. Modern molecular techniques allow scientists to combine several antigens, expanding disease coverage. Subunit vaccines remain limited by the need to include molecular adjuvants that stimulate stronger, broader immune responses.

Get more insights on Vaccine Technologies